Compare · ABT vs KVSA
ABT vs KVSA
Side-by-side comparison of Abbott Laboratories (ABT) and Khosla Ventures Acquisition Co. (KVSA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and KVSA operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $185.36B, about 471.0x KVSA ($393.6M).
- ABT has hit the wire 4 times in the past 4 weeks while KVSA has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 0 for KVSA).
- Company
- Abbott Laboratories
- Khosla Ventures Acquisition Co.
- Price
- $105.52-1.52%
- $10.73+2.68%
- Market cap
- $185.36B
- $393.6M
- 1M return
- +10.33%
- -
- 1Y return
- -18.80%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Khosla Ventures Acquisition Co.
Khosla Ventures Acquisition Co. focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded in 2021 and is based in Menlo Park, California.
Latest ABT
- SEC Form 10-Q filed by Abbott Laboratories
- FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
- Abbott Laboratories filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Abbott Reports Second-Quarter 2026 Results and Raises Full-Year EPS Guidance
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Roman Michael F
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- EXECUTIVE VICE PRESIDENT Morrone Louis H. covered exercise/tax liability with 269 units of Common shares without par value, decreasing direct ownership by 0.35% to 76,574 units (SEC Form 4)
Latest KVSA
- SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)
- SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)
- SEC Form 15-12G filed by Khosla Ventures Acquisition Co.
- Khosla Ventures Acquisition Co. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form 25-NSE filed by Khosla Ventures Acquisition Co.
- Khosla Ventures Acquisition Reports Redemption Of Public Shares And Subsequent Dissolution
- Khosla Ventures Acquisition Co. Announces Redemption of Public Shares and Subsequent Dissolution
- OpenAI Investor Vinod Khosla Works 80 Hours A Week, Will Use Peter Thiel's Anti-Aging Methods If They Work
- SEC Form 10-Q filed by Khosla Ventures Acquisition Co.
- Khosla Ventures Acquisition Co. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing